Tekmira Pharmaceuticals Corporation Intellectual Property Portfolio Expands With Granting of Key Patents Covering LNP Manufacturing and Mitigation of siRNA Immune Stimulation

GLOBE NEWSWIRE -- Tekmira Pharmaceuticals Corporation, a leading developer of RNA interference (RNAi) therapeutics, announced today that the United States Patent & Trademark Office (USPTO) and the European Patent Office (EPO) have issued key patents covering elements of Tekmira's leading lipid nanoparticle (LNP) technology, which is used to deliver nucleic acid therapeutics, including small interfering RNA (siRNA).